...India Pvt. Ltd. has launched Pneumosil, a pediatric pneumococcal conjugate vaccine it developed with the Program for Appropriate Technology in Health (PATH)...

...rilpivirine (TMC278) Long-acting intramuscular cabotegravir Truvada, emtricitabine/tenofovir Bill & Melinda Gates Foundation Gilead Sciences Inc. Johnson & Johnson National Institutes of Health Program for Appropriate Technology in Health (PATH) U.S...

...of P. falciparum parasitemia, antibody concentration and safety. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...

...anywhere. In 2015, EMA’s CHMP recommended its approval. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...

...vaccine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in July. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...

...artemisinin. That pathway only required expression of up to six plant genes. According to the Program for Appropriate Technology in Health (PATH)...
...and Institutions Mentioned Antheia Inc., Menlo Park, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Program for Appropriate Technology in Health (PATH)...

...in national immunization programs once it is approved. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...

...third trimester of pregnancy and in healthy elderly subjects. In 2012, Novavax and the not-for-profit Program for Appropriate Technology in Health (PATH)...

...global vaccine business unit, effective Dec. 1, formerly director of vaccine development global program at Program for Appropriate Technology in Health...

...50 healthy women in the third trimester of pregnancy. In 2012, Novavax and the not-for-profit Program for Appropriate Technology in Health (PATH)...